Tci Wealth Advisors, Inc. Madrigal Pharmaceuticals, Inc. Transaction History

Tci Wealth Advisors, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 03, 2023	BUY	$231.06 - $307.08 $10,628 - $14,125	46 New	46 $11,000
Q2 2022 Jul 19, 2022	SELL	$58.04 - $100.2 $3,018 - $5,210	-52 Closed	0 $0
Q1 2022 Apr 29, 2022	BUY	$55.89 - $101.89 $2,906 - $5,298	52 New	52 $5,000
Q2 2021 Aug 02, 2021	SELL	$97.2 - $137.59 $1,555 - $2,201	-16 Closed	0 $0
Q1 2021 Apr 29, 2021	BUY	$108.54 - $125.2 $1,736 - $2,003	16 New	16 $2,000
Q4 2019 Jan 27, 2020	SELL	$84.28 - $118.5 $421 - $592	-5 Closed	0 $0
Q2 2019 Jul 23, 2019	SELL	$91.13 - $142.5 $455 - $712	-5 Reduced 50.0%	5 $1,000
Q4 2018 Jan 17, 2019	BUY	$94.77 - $215.54 $947 - $2,155	10 New	10 $1,000

336

22.3M

960K

940K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.84B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Tci Wealth Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Tci Wealth Advisors, Inc. with notifications on news.